RT journal article
T1 Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis
A1 Dodero-Anillo, Jose Manuel
A1 Lozano-Cuadra, Inmaculada Concepción
A1 Rios-Sanchez, Esmeralda
A1 Pedrosa-Martínez, María José
A1 Ruiz Carrascosa, José Carlos
A1 Galán-Gutierrez, Manuel
A1 Armario Hita, José Carlos
A2 Medicina
K1 psoriasis
K1 biologic
K1 therapeutic interval
K1 PASI
K1 optimise
K1 infliximab
K1 adalimumab
K1 etanercept
K1 therapeutic drug monitoring
AB In our clinical experience, more than half of patients do not present a complete responseto biologic drugs, or drug loses its efficacy over time. Plasma determinations of drug and antidrugantibodies levels are an objective tool for optimisation in these patients; however, establishedtherapeutic ranges are not suitable, so the objective of this study was to study these patients andoptimise their healthcare. We have made a retrospective, observational study, using data of plasmalevels of drugs and anti-drugs antibodies of infliximab, adalimumab or Etanercept, we summarise alldata and make a study of sensitivity, specificity, positive and negative predictive value on currenttherapeutic ranges. We have found a statistically significant association between subtherapeuticlevels and therapeutic failure in psoriasis treated with infliximab and adalimumab. New rangeswere found with higher sensitivity than the established ones, we propose 2–10  g/mL therapeuticrange for infliximab, 3–11  g/mL for adalimumab, and 1–7  g/mL for etanercept. In conclusion,levels of drug and anti-drug antibodies are a decisive tool for predicting therapeutic response. Thecurrent therapeutic ranges may have minimum values that are excessively high, owing to whichlowering them significantly increases the sensitivity of the test in all cases, and negative predictivevalue in the case of etanercept. Further prospective studies are needed to prove the usefulness ofthese new ranges.
PB MDPI
SN 2075-1729
YR 2022
FD 2022-12-10
LK http://hdl.handle.net/10498/29338
UL http://hdl.handle.net/10498/29338
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 13-nov-2026